Page 1

OnKureⓇ THERAPEUTICS EXHIBIT 99.1 OnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights -- Executing IND - enabling activities for next - generation PI3Ka pan - mutant selective candidates OKI - 345 in breast cancer and OKI - 355 in vascular anomalies , with IND submissions planned for 1H 2027 Hosted a Key Opinion Leader event highlighting the evolving PI3Ka treatment landscape and the scientific rationale supporting OnKure's next - generation PI3Ka pan - mutant inhibitor programs - Participated as an exhibitor and sponsor at the ISSVA World Congress 2026 in Philadelphia , supporting engagement with leading vascular anomalies clinicians and researchers -- $ 176 million of cash , cash equivalents and marketable securities expected to fund operations into 2029 BOULDER , CO , August 4 , 2026 -- OnKure Therapeutics , Inc. ( Nasdaq : OKUR ) , a clinical - stage biopharmaceutical company focused on developing novel precision medicines , today reported financial results for the second quarter ended June 30 , 2026 , and provided recent business highlights . " Following our strategic transformation earlier this year , we continue to advance our next - generation PI3Ka pan - mutant selective inhibitor pipeline , which we believe represents the most compelling opportunity to deliver differentiated therapies across PI3Ka - driven diseases , " said Nicholas Saccomano , Ph.D. , President and Chief Executive Officer of OnKure . " Both OKI- 355 and OKI - 345 continue to advance through IND - enabling activities and remain on track for planned IND submissions in the first half of 2027. We believe the combination of our chemistry platform and deep understanding of PI3Ka biology positions us to develop differentiated therapies with the potential to meaningfully improve outcomes for patients . Our recent Key Opinion Leader event reinforced the scientific rationale underpinning our strategy and highlighted the significant opportunity for next - generation PI3Ka pan - mutant selective inhibitors to overcome the limitations of current therapies across multiple disease settings . " Vascular Anomalies OnKure continues to advance OKI - 355 , a next - generation PI3Ka pan - mutant - selective inhibitor candidate announced in March 2026 to lead its development pipeline in vascular anomalies . OKI - 355 has been designed to selectively inhibit mutant PI3Ka while sparing wildtype PI3Ka , potentially enabling a wider therapeutic index and avoidance of class - limiting toxicities . High and sustained target coverage across all hotspot PI3Ka mutations can support the potential for deep and durable responses in vascular anomalies . Onkure plans to submit an Investigational New Drug ( IND ) application to the U.S. Food and Drug Administration ( FDA ) for OKI - 355 in the first half of 2027 . Additionally , earlier this year , OnKure initiated a discovery research program to expand its vascular anomalies pipeline beyond targeting PI3Ka . Breast Cancer In breast cancer , OnKure continues to advance OKI - 345 , a next - generation PI3Kapan - mutant - selective inhibitor candidate selected in March 2026. OKI - 345 has been designed to selectively inhibit mutant